Advertisement

Topics

Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials

16:30 EST 9 Nov 2017 | BioMedReports - Blog

"During the third quarter, we made significant progress with our clinical stage programs.  We partnered with Vectura to develop Pulmatrix's drug candidate, PUR0200, for chronic

Read more...

Original Article: Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials

NEXT ARTICLE

More From BioPortfolio on "Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...